Lakefront Biotherapeutics (LKFT) vs Zymeworks (ZYME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Zymeworks (ZYME) has outperformed Lakefront Biotherapeutics (LKFT) over the past year, gaining 60.8% versus a loss of 14.1%. Over five years, ZYME leads with a +2.3% price change compared with -43.9% for LKFT. Lakefront Biotherapeutics is the larger company by market cap ($1.96 billion vs $1.90 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LKFT | ZYME |
|---|---|---|
| Share price | $30.00 | $26.53 |
| Market cap | $1.96B | $1.90B |
| 1-day change | +2.32% | +3.43% |
| YTD return | -8.26% | +0.76% |
| 1-year return | -14.11% | +60.79% |
| 5-year return | -43.95% | +2.27% |
| P/E ratio (TTM) | 2.85 | — |
| Forward P/E | — | 30.43 |
| EPS (TTM) | $10.52 | $-2.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $36.24 | $31.34 |
| 52-week low | $25.68 | $16.00 |
| Distance from 52-week high | -17.22% | -15.35% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +0.60% | +55.33% |
| Average volume | 265.76K | 673.06K |
| Shares outstanding | 65.48M | 71.20M |
| Employees | 196 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZYME has outperformed LKFT by 74.9 percentage points over the past year.
About Lakefront Biotherapeutics
LKFT stock →Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Health Care · Biotechnology: Pharmaceutical Preparations · 196 employees
About Zymeworks
ZYME stock →Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
LKFT vs ZYME FAQ
Which is bigger, Lakefront Biotherapeutics or Zymeworks?
Lakefront Biotherapeutics (LKFT) is larger, with a market capitalization of $1.96B compared with $1.90B for Zymeworks (ZYME).
Which stock has performed better over the past year, LKFT or ZYME?
ZYME returned +60.79% over the past 12 months, compared with -14.11% for LKFT (price return, excluding dividends). Past performance does not predict future results.
Are Lakefront Biotherapeutics and Zymeworks in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.